NOTCH1 and adrenal cortex carcinoma: While further studies in additional ACC in vitro models (once established) and PDXs are required to determine whether mutation-independent NOTCH pathway activation may also help predict response to NOTCH inhibitors, particularly when used in combination with other agents [37, 63, 77], our data emphasize the need to carefully assess ACCs for NOTCH1 activating mutations when selecting patients for treatment with GSIs.